Q3 2025 Hikal Ltd Earnings Call Transcript
Key Points
- Hikal Ltd (BOM:524735) reported a revenue of INR448 crore in Q3 FY25, with an EBITDA growth of 11% year-over-year.
- The company has capitalized its new multipurpose facility at Panoli, expecting a ramp-up over the next two to three years.
- Hikal Ltd's pharmaceutical business reported a significant increase in EBIT by 450 basis points year-over-year, driven by an improved product mix and operating leverage.
- The company is witnessing recovery in its APR business due to improved volume uptakes and expects steady performance in the coming quarters.
- Hikal Ltd is experiencing significant positive traction in its CDMO business, with several projects moving towards validation and commercialization.
- Hikal Ltd faces pricing pressure and dumping from Chinese competitors, particularly in the generics and commodity products segment.
- The company's crop protection business is experiencing challenges due to ongoing pricing pressures and volume pressures from the global slowdown.
- There has been a slight drop in EBIT margins for the pharmaceutical business in the current quarter, attributed to changes in product mix and timing of customer shipments.
- The company has not grown significantly in value terms, with crop protection growth at 3.3% and pharmaceutical growth at 7.1% in value terms.
- Hikal Ltd's gross debt stands at INR731 crore as of December 31, 2024, indicating a significant financial obligation.
Ladies and gentlemen, good day and welcome to Hikal Limited Q3 and FY25 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
Before we move on to the presentation, a small disclaimer to all the participants. This conference call may contain forward-looking statements about the company which are based on beliefs, opinions and expectations of the company as on the date of this call. These statements are not the guarantees of future performance and involves risk and uncertainties that are difficult to predict.
I now hand the conference over to Mr. Sameer Hiremath, Managing Director, Hikal Limited. Thank you and over to you, Sameer.
Thank you, ladies and gentlemen, good afternoon and a warm welcome to all of you. We extend our gratitude to all of you for participating in our Q3 and nine months FY25 results conference call.
We are pleased to provide you with an update on the progress made by your company. We trust that you have had the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
